For the active immunisation of dogs to prevent mortality and disease caused by canine distemper virus and canine parvovirus; to prevent mortality and reduce clinical signs due to infectious canine hepatitis and Leptospira interrogans serogroups canicola and icterohaemorrhagiae; to reduce clinical signs and infection caused by canine adenovirus 2; to reduce clinical signs and shedding caused by canine parainfluenza virus and to reduce infection at the intestinal level caused by canine coronavirus. The onset of immunity is from two weeks after the second vaccination. The duration of immunity is at least three years for the canine distemper virus, canine adenovirus and canine parvovirus fractions and at least one year for all other antigens. After one year, only a reduction of oculo-nasal discharge has been demonstrated following canine parainfluenza challenge.

Demonstration of onset and of one year duration of immunity against canine parvovirus was conducted by challenge studies using virulent CPV2a and CPV2b. Demonstration of three years duration of immunity against canine parvovirus was conducted by challenge study using virulent CPV2b only.